Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 349-356

  Gamble, Tondalaya ^a   Sand, Peter ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Overactive bladder syndrome; Oxybutynin; Transdermal delivery

Indexed keywords

EID: 84859458634     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3417     Document Type: Review

References (52)

1. Anderson R. U, Mobley D, Blank B, et al. 1999. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol, 161:1809-12.
2. Andersson K.E. 2002. Bladder activation: afferent mechanisms. Urology, 59:43-50.
3. Andersson K. E, Appell R, Cardozo LD, et al. 1999. The pharmacological treatment of urinary incontinence. BJU Int, 84:923-47.
4. Andersson K. E, Yoshida M. 2003. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol, 43:1-5.
5. Appell R. A, Chancellor MB, Zobrist RH, et al. 2003. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc, 78:696-702.
6. Birder L.A. 2005. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol, 289:F489-95.
7. Brading A.F. 2007. Acetylcholine and the overactive bladder. Eur Urol, 51:881-3.
8. Burgio K. L, Locher JL, Goode PS. 2000. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc, 48:370-4.
9. Chancellor M. B, Appell RA, Sathyan G, et al. 2001. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther, 23:753-60.
10. Chapple C.R. 2000. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology, 55:33-46; discussion 50.
11. Chapple C., Khullar V, Gabriel Z, et al. 2005. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol, 48:5-26.
12. Davila G. W, Daugherty CA, Sanders SW. 2001. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol, 166:140-5.
13. Davila G. W, Starkman JS, Dmochowski RR. 2006. Transdermal oxybutynin for overactive bladder. Urol Clin North Am, 33:455-63, viii.
14. De Laet K, De Wachter S, Wyndaele JJ. 2006. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn, 25:156-61.
15. Dmochowski R. R, Davila GW, Zinner NR, et al. 2002. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol, 168:580-6.
16. Dmochowski R. R, Nitti V, Staskin D, et al. 2005. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol, 23:263-70.
17. Dmochowski R. R, Sand PK, Zinner NR, et al. 2003. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 62:237-42.
18. Fabiyi A. C, Brading AF. 2006. The use of the isolated mouse whole bladder for investigating bladder overactivity. J Pharmacol Exp Ther, 319:1386-94.
19. Gibbs C. F, Johnson TM 2nd, Ouslander JG. 2007. Office management of geriatric urinary incontinence. Am J Med, 120:211-20.
20. Goldberg R. P, Sand PK. 2002. Pathophysiology of the overactive bladder. Clin Obstet Gynecol, 45:182-92.
21. Hegde S.S. 2006. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol, 147(Suppl 2):S80-7.
22. Homma Y., KawabeK. 2004, Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol, 22:251-6
23. Homma Y., Koyama N. 2006. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. Neurourol Urodyn, 25:228-35.
24. Homma Y., Yamaguchi O, Hayashi K. 2006. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology, 68:560-4.
25. Hu T. W, Wagner TH. 2005. Health-related consequences of overactive bladder: an economic perspective. BJU Int, 96(Suppl 1):43-5.
26. Irwin D. E, Abrams P, Milsom I, et al. 2008. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int, 101:1381-7.
27. Irwin D. E, Milsom I, Hunskaar S, et al. 2006. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 50:1306-14; discussion 1314-5.
28. Kelleher C., Pleil A, Reese P, et al. 2004. How much is enough and who says so? BJOG, 111: 605-12.
29. Kullar V., Chapple C, Zagava G, et al. 2006. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology, 68:338-48.
30. Kumar V., Cross RL, Chess-Williams R, et al. 2005. Recent advances in basic science for overactive bladder. Curr Opin Urol, 15:222-6.
31. Lavelle J. P, Karram M, Chu FM, et al. 2006. Management of incontinence for family practice physicians. Am J Med, 119: 37-40.
32. Marschall-Kehrel D, Roberts RG, Brubaker L. 2006. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology, 68:29-37.
33. Milsom I., Abrams P, Cardozo L, et al. 2001. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int, 87:760-6.
34. Milsom I., Stewart W, Thuroff J. 2000. The prevalence of overactive bladder. Am J Manag Care, 6:S565-73.
35. Oki T., Toma-Okura A, Yamada S. 2006. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther, 316:1137-45.
36. Ouslander J.G. 2004. Management of overactive bladder. N Engl J Med, 350:786-99.
37. Oxytrol [package insert]. 2003. Corona, California. Watson Pharma. Incorporated.
38. Portera S. G, Lipscomb GH. 1998. Pharmacologic therapy for urinary incontinence and voiding dysfunctions. Clin Obstet Gynecol, 41:691-701.
39. Sahai A., Mallina R, Dowson C, et al. 2008. Evolution of transdermal oxybutynin in the treatment of overactive bladder. Int J Clin Pract, 62:167-70.
40. Sand P. K, Goldberg RP, Dmochowski RR, et al. 2006a. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol, 195:1730-5.
41. Sand P. K, Kelleher CJ, Pizzi L, et al. 2006b. Effect of treatment for overactive bladder on work productivity [abstract]. Int Urogynecol J, 17(Suppl 2):S101-S52.
42. Sand P. K, Zinner N, Newman D, et al. 2007. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int, 99:836-44.
43. Scarpero H. M, Dmochowski RR. 2003. Muscarinic receptors: what we know. Curr Urol Rep, 4:421-8.
44. Staskin D.R. 2003. Transdermal systems for overactive bladder: principles and practice. Rev Urol, 5(Suppl 8):S26-30.
45. Stewart W. F, Van Rooyen JB, Cundiff GW, et al. 2003. Prevalence and burden of overactive bladder in the United States. World J Urol, 20:327-36.
46. Temml C., Haidinger G, Schmidbauer J, et al. 2000. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn, 19:259-71.
47. Thuroff J. W, Bunke B, Ebner A, et al. 1991. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol, 145:813-6; discussion 816-7.
48. Voytas J. 2002. The role of geriatricians and family practitioners in the treatment of overactive bladder and incontinence. Rev Urol, 4(Suppl 4):S44-9.
49. Wagner T. H, Hu TW, Bentkover J, et al. 2002. Health-related consequences of overactive bladder. Am J Manag Care, 8:S598-607.
50. Yip S. K, Chan A, Pang S, et al. 2003. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol, 188:1244-8.
51. Winkler H. A, Sand PK. 1998. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J, 9:100-2.
52. Zobrist R. H, Quan D, Thomas HM, et al. 2003. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res, 20:103-9.